Binding of the quinolone drug norfloxacin to gyrase and DNA has been investigated. We have detected binding to gyrase-DNA complex but find no significant binding to either gyrase or DNA alone. Enzyme containing gyrase A protein with the mutation Ser-83 to Trp (conferring quinolone resistance) showed greatly reduced drug binding.
The target of the quinolone antibacterial agents is thought to be DNA gyrase. The enzyme from Escherichia coli consists of two A and two B subunits (the products of the gyrA and gyrB genes, respectively) and is responsible for catalyzing topological changes in DNA (for a review, see reference 11) . A recent model for the mechanism by which quinolones inhibit gyrase envisages the binding of drug by hydrogen bonding to a single-stranded DNA pocket at the active site of the enzyme (13) .
We have used a rapid gel-filtration (spin column) technique (7) as a means of studying binding; free ligand is retained on the column, and ligand bound to macromolecule is eluted. This approach has previously been used to address the question of quinolone interaction with gyrase and DNA (12) .
[3H]norfloxacin ([3H]NFX), a gift from L. L. Shen (Abbott Laboratories), was repurified by reverse-phase highpressure liquid chromatography according to the recommended procedure (12) . Gyrase subunits were prepared from overproducing strains (5) and preincubated together in equimolar concentrations for 30 min at 25°C to form the A2B2 complex. Typical specific activities were -106 U/mg for GyrA proteins and -6 x 104 U/mg for GyrB (10) . In addition to the wild-type proteins, GyrA containing the mutation Ser-83 to Trp, which is known to lead to high-level resistance to quinolones (1, 16) (5) .
The DNA used was a 147-bp fragment containing the major gyrase cleavage site from pBR322 (3), which has been shown to be cleaved by gyrase at a single site into fragments of 69 and 78 bp (2) . Incubation of the 147-bp fragment (86 nM) with gyrase (700 nM) and NFX (2.5 ,ug/ml; 7,800 nM) at 25°C for 3 h, followed by the addition of sodium dodecyl sulfate (SDS) and proteinase K and a further 30 min of incubation at 37°C, leads to complete cleavage of this fragment at the expected site (2, 3, 14) . The 147-bp fragment was prepared from plasmid pSTD147 as described previously (2). Gel retardation assays (9) (12) . Crucially, this binding was virtually abolished for complexes of the GyrATrp83 enzyme and DNA. Other experiments showed that enzyme-DNA complex prepared with another quinolone-resistant protein, GyrAAXa-83 (6) , bound approximately threefold less drug than wild-type complex did (data not shown).
In a second series of experiments, DNA cleavage (4) was used as an indirect monitor of binding. When the related quinolone ciprofloxacin (CFX) was used, no binding to either wild-type gyrase or the DNA alone was found ( Table  2) . A series of assays was performed in which one component (gyrase, DNA, or CFX) was omitted from the initial reaction mixture and added after the other two components had been incubated for 2 h and passed through a spin column. The new reaction mixture was then incubated for a further 2 h prior to the addition of 0.2% SDS and 1 mg of proteinase K per ml and 30 min of incubation at 37°C. When gyrase and DNA were incubated together and CFX (20 pug/ml; 60 pM) was added following centrifugation, cleavage was observed ( It should be pointed out that the centrifugation involved in a spin column assay means that the experiments are not performed under true equilibrium conditions. These results do not, therefore, rule out the possibilities that some weak interaction may be occurring between quinolones and either gyrase or DNA alone and that dissociation may occur during centrifugation.
Control experiments have revealed comparable extents of DNA cleavage with and without centrifugation. The stability of the gyrase-DNA-quinolone complex following centrifugation was also confirmed. After incubation of gyrase and DNA with unlabelled CFX for 2 h, the reaction mixture was passed through a spin column and incubation continued for a further 0 to 3 h prior to the addition of SDS and proteinase K. The extent of cleavage in samples 3 h after incubation was identical to that in samples treated immediately after centrifugation, implying that the ternary complex is stable throughout this period.
A recent model proposes that quinolones bind to a singlestranded DNA pocket at the active site of the enzyme (13).
Yoshida and coworkers have commented that this model underplays the significance of quinolone resistance arising from gyrase mutations (15); a fuller critique is given elsewhere (8, 11) . Supercoiling assays reveal that gyrase with GyrATrp-83 subunits is able to perform the introduction of negative supercoils into closed circular DNA as efficiently as the wild-type enzyme (14) . In so doing it would be expected to open up the DNA in an identical way to its quinolone- 
